Center for Addiction Medicine

Jordan Smoller, MD, MS, ScD

Jordan Smoller Headshot

Associate Chief for Research for the Department of Psychiatry, Director of Psychiatric Genetics and of the Psychiatric and Neurodevelopment Genetics Unit and the Precision Medicine Unit, Center for Genomic Medicine, Director of the Omics Unit of the Division of Clinical Research Program at Massachusetts General Hospital. Professor of Psychiatry at Harvard Medical School, Professor of Epidemiology at Harvard School of Public Health

Contact:     (617) 724-0835


Dr Smoller leads a research program focused on understanding the genetic and environmental determinants of psychiatric disorders through large-scale genomic/biomarker studies of neuropsychiatric phenotypes, including the international Psychiatric Genomics Consortium (PGC). A strong interest is the biologic / genetic basis for high rates of comorbidity between psychiatric and addictive disorders such as schizophrenia and tobacco dependence. His has extensive experience with the design and conduct of psychiatric genetic studies, including behavioral and neuroimaging intermediate phenotype studies, as well as gene-environment interaction analyses. Dr. Smoller collaborates with Drs. Evins, Fava, Janes and Dougherty, serves as genetics consultant on Dr. Evins’ K24, as co-mentor with Dr. Evins for genetics aims and training of a NIDA K23 (Schuster). He currently mentors four pre-doctoral and three post-doctoral trainees.


Current Projects

Genetic analysis of the international cohort collection for bipolar disorder

NIMH R01 MH106547 2015 – 18

This project will perform genomic characterization of the large International Cohort Collection for Bipolar Disorder to identify common and rare genetic risk loci for bipolar disorder, explore clinically relevant genetic risk models, and characterize the spectrum of genotype-phenotype relevant to bipolar disorder


A New England enrollment center for the PMI cohort program

NIH/Office of the Director 1OT2OD024612  2016 – 18

The main goal of this project is to recruit 10,000 subjects into the Precision Medicine Initiative, and enters heir DNA samples into the biobank and link to EHR data.


Neural and genetic basis of negative valance traits

NIMH R01 MH101486  2013 – 18

The goal of this project will inform the development of RDoC criteria for the negative valence domain and the larger goal of grounding mental disorders in underlying biological and psychological dimensions


The development and neural bases of emotion processing

NIMH R01 MH07882915A1

2012 – 18

The goal of this project is to examine early development of emotion processing capacities in infants and their neural basis. The role of genetic variation on individual differences in fear processing will be explored.


eMERGE phase III clinical center at Partners HealthCare

NHGRI U01HG008685 2015 – 19

The discovery and clinical use of genetic variants associated with both rare Mendelian and more common complex diseases promises to dramatically change the practice of medicine. The eMERGE III Clinical Center at Partners HealthCare will leverage a large Biobank and a rich electronic medical record to define the phenotypic impact of mutations emerging from sequencing and then return results on selected variants to Biobank participants using a clinical trial.

Understanding the connections among genes, environment, family processes, and mental health

NIMH R01 MH110872 2017 – 21

This project will collect biosamples as well as measures of social and family environment and psychopathology in a long-term community and family panel study in Nepal to examine genetic and environmental predictors of risk and resilience for psychiatric disorders and family outcomes.

%d bloggers like this: